Sarcopenia

Print

In December 2009, the Metabolic Disorders Steering Committee launched its third project: Establishing Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults.

Six grants were awarded by FNIH to the following Principal Investigators and academic institutions:  

1. Dawn Alley, University of Maryland;
2. Peggy Cawthon, California Pacific Medical Center Research Institute;
3. Thuy-Tien Dam, Columbia University;
4. Anne Kenny, University of Connecticut;
5. Robert McLean, Harvard University; and,
6. Carmen Sceppa, Northeastern University.  

For performing data analysis over the course of 12 months on many observational and clinical trials as a part of the Phase I of the Sarcopenia Project. The Sarcopenia Project Team Chair is Dr. Stephanie Studenski from the University of Pittsburgh who is also going to head the Coordinating Center for the data analysis. The project currently has 4 pharmaceutical company sponsors, and FNIH is in the fundraising stages for the second phase of the project, which will involve the organization of the Sarcopenia Consensus Summit and the publication of a journal supplement with all the results from the Phase I data analysis findings. 

The kick-off meeting of the PI team took place on March 8-9, 2010 in Bethesda, MD. The consensus summit is being planned for Summer 2011.

  • About Biomarkers

    Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention. More

  • Join Us

    Become a Member
    Learn how you can join and support The Biomarkers Consortium.

    The Biomarkers Consortium embraces government, industry, patient advocacy groups, and non-profit organizations, each of which has a stake in the development of biomarker technology.

  • Latest News

    THE BIOMARKERS CONSORTIUM LAUNCHES I-SPY 2 BREAST CANCER CLINICAL TRIAL:  Click here to read the press release.

    March 17, 2010 -- Announcing the launch of the Biomarkers Consortium I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and moLecular analysis): An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy), which is taking place today from 9-10:30 a.m. ET at the National Press Club, Washington, DC.  Click here for more information.

    View the Web Cast

     

    Six awardees conducting data analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults: Click here to read

    The Metabolic Disorders Steering Committee releases strategy for Mathematical Modeling in Atherosclerosis:  Details

    PRESS RELEASE:  The Biomarkers Consortium Completes First Project to Show That Adiponectin is a Predictive Biomarker for Type 2 Diabetes:  Click here to read

    RFP for Data Analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults.  Due Date: September 8, 2009.  Click here to read.

     

    Available Now: The Biomarkers Consortium Report, Volume 1, Issue 1, May 2009. Click Here to Read

    The Metabolic Disorders Steering Committee Prioritized Areas of Unmet Need: As advertised in Volume 58, No. 4, April 2009 issue of Diabetes.  Click Here to read.

    Presentations Available from the Beta Cell Function Symposium. Click here for agenda.